Several trials have shown the activity of thalidomide (THAL) in relapsed multiple myeloma (MM) patients failing PBSCT or conventional chemotherapy. PBSCT is considered standard treatment for most patients requiring therapy for MM; however, patients with VAD-resistant disease may not be able to receive PBSCT due to rapidly advancing disease. We report four cases of VAD-refractory MM salvaged with THAL ؉ VAD followed by PBSCT. All patients underwent stem cell mobilization with cyclophosphamide (Cy) (4.5 g/m 2 ) and GMCSF. Melphalan (140-200 mg/m 2 ) was given as conditioning. All patients engrafted within 12-16 days after PBSCT. Day ؉100 evaluation showed the following: very good partial response (n ‫؍‬ 1) and complete response (n ‫؍‬ 3). After a median follow-up to 153 days, two patients continue to take THAL with no signs of disease progression. One patient developed CHF and was taken off THAL while another patient has died of progressive disease while on THAL (MTD 50 mg). In conclusion, VAD-refractory patients were salvaged with the addition of THAL to VAD. They were subsequently able to undergo autologous PBSCT for MM, which will likely improve their overall survival. This suggests that THAL and other related immunomodulatory drugs may prove useful for initial MM therapy in combination with standard chemotherapy followed by PBSCT. Bone Marrow Transplantation (2002) 29, 577-580. DOI: 10.1038/sj/bmt/1703522 Keywords: multiple myeloma; peripheral blood stem cell transplantation; thalidomide VAD (vincristine, adriamycin, dexamethasone) is considered standard, first-line therapy for multiple myeloma (MM).
modest activity against VAD-refractory multiple myeloma. 3 In addition, different combination chemotherapy regimens have limited effect. These include vincristine and etoposide, etoposide, dexamethasone, Ara-C and cisplatin (EDAP) and DAP alone. 4, 5 The hyper C-VAD regimen (twice daily cyclophosphamide (Cy) and VAD) produced a 40% response rate and a median remission duration of only 8 months in VAD-refractory MM patients. 6 Thus new approaches are necessary to treat MM refractory to standard treatment.
Thalidomide (THAL) is a novel anti-myeloma agent with 25 to 35% response rates in heavily pre-treated patients. 7, 8 Singhal et al 7 reported the results of 84 patients with previously treated and progressive MM who were treated with THAL as a single agent. Ten percent of patients had complete or nearly complete remission (CR) and 32% had a reduction in serum or urine paraprotein level of at least 25%. After 12 months of follow-up, 22% of the study patients remained event free and 58% were alive. Juliusson et al 8 reported the results of 23 advanced and heavily pretreated MM patients who were treated with THAL. Ten of 23 (43%) achieved a partial response (PR) and six had minor responses (MR) or stable disease (SD).
There is clear evidence supporting the role of THAL for patients with relapsed or progressive MM after stem cell transplantation (SCT) or conventional chemotherapy. [7] [8] [9] [10] However, there are no reports of VAD-refractory patients salvaged with THAL plus VAD who were able to go on to autologous peripheral blood stem cell transplantation (PBSCT). We report four cases of VAD-refractory MM in patients who were treated with autologous PBSCT after achieving partial or complete responses with the addition of THAL to VAD chemotherapy.
The objective was to determine if the addition of THAL would salvage VAD-refractory patients and allow them to proceed to autologous PBSCT.
Methods
This is a retrospective chart review of four patients with VAD-refractory MM, from the RPCI (Roswell Park Cancer Institute) patient database. Patients were treated with standard doses of monthly VAD (vincristine 0.4-0.5 mg/day continuous infusion (CIVI) daily for 4 days, doxorubicin (adriamycin) 9-10 mg/m 2 CIVI daily for 4 days and dexamethasone 40 mg orally daily on days 1-4, 9-12 and 17-20). Response was assessed by monoclonal (M) protein quantitation in serum or urine. The criteria used for evaluation of response are described in Table 1 . 7 Treatment response was assessed after standard VAD therapy (before THAL), after VAD and THAL therapy (before transplantation), day ϩ100 post autologous PBSCT and at last follow-up. Patient characteristics and treatment modalities are outlined in Table 2 . All patients were continued on THAL through stem cell mobilization and autotransplant. Stem cell mobilization consisted of Cy (4.5 g/m 2 ) and GM-CSF and collection of a minimum of 2 ϫ Tables 3  and 4 .
Results

Patient responses to treatment are outlined in
Patient 1 presented with fatigue and rib pain. There were 84.5% plasma cells on bone marrow biopsy, diffuse lytic M protein ϭ monoclonal protein; Tx ϭ therapy; THAL ϭ thalidomide; PBSCT ϭ peripheral blood stem cell transplant; M ϭ male; VAD ϭ vincristine, adriamycin, dexamethasone; Cy ϭ cyclophosphamide; mobil ϭ mobilization; M/P ϭ melphalan/prednisone; wks ϭ weeks; F ϭ female.
lesions and serum creatinine (Cr) was elevated at 1.8 mg/dl (normal 0.8-1.5 mg/dl). After four cycles of VAD he had progressive disease (PD). He was started on THAL at 100 mg daily, with escalation by 50 mg every 2 weeks. The maximum tolerated dose (MTD) was 300 mg daily due to fatigue. He was treated with THAL and VAD ϫ 3 cycles and underwent stem cell mobilization and collection. The response to salvage was evaluated as a PR. The patient underwent autologous PBSCT without complications. Day ϩ100 evaluation demonstrated a very good partial response (VGPR). The patient remains in a VGPR while taking THAL 250 mg daily at last follow-up, 217 days post autologous PBSCT. Patient 2 presented with fatigue and other symptoms of anemia. Initial bone marrow biopsy demonstrated 50% plasma cells. He received VAD ϫ 2 cycles. Although biochemical markers improved he developed progressive disease (PD) with a base of the skull plasmacytoma and left ninth cranial nerve palsy. He started salvage with THAL at 200 mg daily that was reduced to 100 mg daily due to constipation. He also received 4200 cGy of radiation to the base of the skull followed by Cy for stem cell mobilization. He was assessed to be in PR at restaging. He underwent PBSCT without complications. At day ϩ100, he was assessed to be in CR. The patient continued THAL 50 mg daily (reduced due to fatigue). He relapsed with intracranial parenchymal myelomatous disease (confirmed by brain biopsy) approximately 240 days post transplant. Despite Table 3 Responses to initial treatment and addition of thalidomide high-dose dexamethasone treatment, he died of disease approximately 270 days following PBSCT. Patient 3 presented with bone pain and anemia and was treated with melphalan and prednisone for six cycles. He had progressive disease at 12 months and was treated with oral Cy for 4 weeks along with radiation to a large lytic lesion in the left scapula (2500 cGy) with PD. He was referred to our center and further evaluation by renal ultrasound demonstrated enlarged kidneys consistent with myelomatous involvement. He was treated with VAD ϫ 2 cycles. Restaging showed PD. He was started on THAL salvage at 100 mg daily, which was escalated weekly to 400 mg daily. He attained CR and underwent autologous PBSCT without complications. His day ϩ100 evaluation demonstrated CR. He continued to be in CR at last follow up (day ϩ 640) on THAL 400 mg daily.
Patient 4 presented with severe neck pain and anemia and was found to have a large C4 vertebral plasmacytoma. She underwent surgical vertebral stabilization along with two cycles of melphalan and prednisone with PD. She was switched to VAD for six cycles. Re-evaluation demonstrated MR. She started THAL at 50 mg per day and escalated weekly to 200 mg daily. Her pre-transplant evaluation demonstrated a VGPR. She underwent autologous PBSCT without complications, except that the dose of THAL was decreased to 50 mg daily due to congestive heart failure. Day 100 evaluation demonstrated disapBone Marrow Transplantation pearance of the M protein (IgG kappa) and development of a new M protein (IgM lambda), normalization of serum ␤2M level and 1% plasma cells on bone marrow biopsy. She was evaluated as a CR as the IgM lambda M protein was disappearing at follow-up 1 month later. THAL has been withheld recently due to persistent congestive heart failure.
These four patients would have been considered poor candidates for autologous PBSCT because of persistent or progressive disease. In particular, due to renal insufficiency and rapidly progressive disease, patients 1 and 3 would not have undergone PBSCT without THAL therapy. THAL was the primary agent that allowed these patients to be salvaged and dramatic responses were seen. All patients had responses ranging from PR to CR. Constipation and fatigue were common side-effects. One patient has mild to moderately severe peripheral neuropathy, which was stable on last follow-up. One patient required cessation of THAL due to congestive heart failure, with a plan to restart once her cardiac status stabilizes. One patient developed central nervous system progression while on low-dose THAL. The dose reduction may have predisposed him to disease progression.
Discussion
THAL has been utilized for the treatment of a variety of malignant and nonmalignant disorders. In particular, THAL is a novel molecule for the treatment of malignant diseases such as MM because of its diverse pharmacologic and immunologic effects. 12 THAL's pleiotrophic effects are mediated, at least in part, through its ability to modulate the immune system. THAL inhibits tumor necrosis factoralpha (TNF-␣) production, IL-1␤, IL-6 secretion by activated peripheral blood mononuclear cells as well as increasing the anti-inflammatory cytokine IL-10 and upregulating T helper 2 (Th2) type immunity. 13 THAL has proven to be a useful agent in the treatment of patients with recurrent or progressive MM who have failed standard therapy or autotransplant. 7, 8, 14, 15 The exact mechanism(s) of the THAL anti-tumor effect is not clear. In addition to immuno-modulatory effects, THAL induces apoptosis in MM cell lines and overcomes drug resistance of MM cells to conventional therapy. 16 The synergistic effects of THAL with chemotherapy have been demonstrated by other investigators. Weber et al 17 reported nine of 26 patients (35%) who had failed therapy with THAL for relapsed MM responded to a combination of THAL and dexamethasone. The Arkansas group has combined THAL with cyclophosphamide, etoposide, adriamycin, cisplatin and dexamethasone (DTPACE) for patients with aggressive MM and plasma cell leukemia with an excellent response rate and no unfavorable effects on stem cell mobilization. 18, 19 Two of the three surviving patients reported in this study continue to take THAL at last follow-up because they progressed during standard therapy. Maintenance of remission on the lower doses of THAL has been reported suggesting that once an initial response has been achieved, lower doses may be sufficient to maintain the response. 15 More data are needed to determine the exact dose-response relationship.
Our experience suggests that THAL combined with the VAD regimen is a reasonable option for patients, who have a MR or PD after VAD chemotherapy alone. This salvage allows patients to undergo autologous PBSCT with excellent response and long-term control of VAD-refractory disease.
